Research ArticleOriginal Article
Open Access

Prevalence of complementary and alternative medicine use in brain tumor patients at King Abdulaziz University Hospital, Jeddah, Saudi Arabia

Abdulgadir Atteiah, Azmi Marouf, Rayan Alhazmi, Albaraa Alghamdi, Khalid Almalki, Faisal Albugamy and Soha A. Alomar
Saudi Medical Journal June 2020, 41 (6) 614-621; DOI: https://doi.org/10.15537/smj.2020.625102

References

  1. ↵
    1. Armstrong TS,
    2. Glbert MR
    (2008) Use of complementary and alternative medical therapy by patients with primary brain tumors. Curr Neurol Neurosci Rep 8:264–268.
    OpenUrlCrossRefPubMed
    1. Schubart JR,
    2. Kinzie MB,
    3. Farace E
    (2008) Caring for the brain tumor patient:family caregiver burden and unmet needs. Neuro Oncol 10:61–72.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Armstrong TS,
    2. Vera-Bolanos E,
    3. Acquaye AA,
    4. Gilbert MR,
    5. Ladha H,
    6. Mendoza T
    (2015) The symptom burden of primary brain tumors:evidence for a core set of tumor-and treatment-related symptoms. Neuro Oncol 18:252–260.
    OpenUrlPubMed
  4. ↵
    Brain Tumors:A handbook for the newly diagnosed, American Brain Tumor Association. Available from URL:https://www.abta.org/wp-content/uploads/2018/03/newly-diagnosed.pdf. [Updated 2014].
  5. ↵
    1. Saudi Health Council
    Cancer incidence report in Saudi Arabia. Available from URL:https://nhic.gov.sa/eServices/Documents/2014.pd. [Updated 2017].
  6. ↵
    1. Eisenberg DM,
    2. Davis RB,
    3. Ettner SL,
    4. Appel S,
    5. Wilkey S,
    6. Van Rompay M,
    7. et al.
    (1998) Trends in alternative medicine use in the United States 1990-1997:results of a follow-up national survey. JAMA 280:1569–1567.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Fan KW
    (2005) National center for complementary and alternative medicine website. J Med Libr Assoc 93:410–412.
    OpenUrl
  8. ↵
    1. Al-Faris EA
    (2000) The pattern of alternative medicine use among patients attending health centres in a military community in Riyadh. J Family Community Med 7:17–25.
    OpenUrl
    1. Al-Faris EA,
    2. Al-Rowais N,
    3. Mohamed AG,
    4. Al-Rukban MO,
    5. Al-Kurdi A,
    6. Balla Al-Noor MA,
    7. et al.
    (2008) Prevalence and pattern of alternative medicine use:the results of a household survey. Ann Saudi Med 28:4–10.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. AlBedah A,
    2. Khalil M,
    3. Elolemy A,
    4. Elsubai I,
    5. Khalil A
    (2011) Hijama (cupping):a review of the evidence. Focus Altern Complement Ther 16:12–16.
    OpenUrl
  11. ↵
    1. Keene MR,
    2. Heslop IM,
    3. Sabesan SS,
    4. Glass BD
    (2019) Complementary and alternative medicine use in cancer:A systematic review. Complement Ther Clin Pract 35:33–47.
    OpenUrl
  12. ↵
    1. Sudairy RA,
    2. Omari AA,
    3. Jarrar M,
    4. Harbi TA,
    5. Jamaan KA,
    6. Tamim H,
    7. et al.
    (2011) Complementary and alternative medicine use among pediatric oncology patients in a tertiary care center, Riyadh, Saudi Arabia. J Clin Oncol 29:e2000.
    OpenUrl
  13. ↵
    1. John GM,
    2. Hershman DL,
    3. Falci L,
    4. Shi Z,
    5. Tsai WY,
    6. Greenlee H
    (2016) Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv 10:850–864.
    OpenUrl
  14. ↵
    1. Ernst E,
    2. White A
    (2000) The BBC survey of complementary medicine use in the UK. Complement Ther Med 8:32–36.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Spinks J,
    2. Hollingsworth B,
    3. Manderson L,
    4. Lin V,
    5. Canaway R
    (2013) Costs and drivers of complementary and alternative medicine (CAM) use in people with type 2 diabetes or cardiovascular disease. Eur J Integr Med 5:44–43.
    OpenUrlCrossRef
  16. ↵
    1. AlBedah AM,
    2. Khalil MK,
    3. Elolemy AT,
    4. Al Mudaiheem AA,
    5. Al Eidi S,
    6. Al-Yahia OA,
    7. et al.
    (2013) The use of and out-of-pocket spending on complementary and alternative medicine in Qassim province, Saudi Arabia. Ann Saudi Med 33:282–289.
    OpenUrlPubMed
  17. ↵
    1. Greenlee H,
    2. Neugut AI,
    3. Falci L,
    4. Hillyer GC,
    5. Buono D,
    6. Mandelblatt JS,
    7. et al.
    (2016) Association between complementary and alternative medicine use and breast cancer chemotherapy initiation:the breast cancer quality of care (BQUAL) study. JAMA 2:1170–1176.
    OpenUrl
  18. ↵
    1. Sweet E,
    2. Dowd F,
    3. Zhou M,
    4. Standish LJ,
    5. Andersen MR
    (2016) The use of complementary and alternative medicine supplements of potential concern during breast cancer chemotherapy. Evid Based Complement Alternat Med 2016:4382687.
    OpenUrl
  19. ↵
    1. Egger S,
    2. Hughes S,
    3. Smith DP,
    4. Chambers S,
    5. Kahn C,
    6. Moxey A,
    7. et al.
    (2018) Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors. PloS One 13:e0193686.
    OpenUrl
    1. Zuniga KB,
    2. Zhao S,
    3. Cedars BE,
    4. Cowan JE,
    5. Kenfield SA,
    6. Van Blarigan EL,
    7. et al.
    (2019) Trends in complementary and alternative medicine use among newly diagnosed prostate cancer patients. J Urol 202:689–695.
    OpenUrl
  21. ↵
    1. Johnson SB,
    2. Park HS,
    3. Gross CP,
    4. James BY
    (2018) Complementary medicine, refusal of conventional cancer therapy, and survival among patients with curable cancers. JAMA Oncol 4:1375–1381.
    OpenUrl
  22. ↵
    1. Richardson MA,
    2. Sanders T,
    3. Palmer JL,
    4. Greisinger A,
    5. Singletary SE
    (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Swisher EM,
    2. Cohn DE,
    3. Goff BA,
    4. Parham J,
    5. Herzog TJ,
    6. Rader JS,
    7. et al.
    (2002) Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol 84:363–367.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Molassiotis A,
    2. Fernandez-Ortega P,
    3. Pud D,
    4. Ozden G,
    5. Scott JA,
    6. Panteli V,
    7. et al.
    (2005) Use of complementary and alternative medicine in cancer patients:a European survey. Ann Oncol 16:655–663.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Keene MR,
    2. Heslop IM,
    3. Sabesan SS,
    4. Glass BD
    (2019) Complementary and alternative medicine use in cancer:A systematic review. Complement Ther Clin Pract 35:33–47.
    OpenUrl
  26. ↵
    1. Abuelgasim KA,
    2. Alsharhan Y,
    3. Alenzi T,
    4. Alhazzani A,
    5. Ali YZ,
    6. Jazieh AR
    (2018) The use of complementary and alternative medicine by patients with cancer:a cross-sectional survey in Saudi Arabia. BMC Complement Altern Med 18:88.
    OpenUrl
  27. ↵
    1. Jazieh AR,
    2. Al Sudairy R,
    3. Abulkhair O,
    4. Alaskar A,
    5. Al Safi F,
    6. Sheblaq N,
    7. et al.
    (2012) Use of complementary and alternative medicine by patients with cancer in Saudi Arabia. J Altern Complement Med 18:1045–1049.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Verhoef MJ,
    2. Balneaves LG,
    3. Boon HS,
    4. Vroegindewey A
    (2005) Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients:a systematic review. Integr Cancer Ther 4:274–286.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Hwang JH,
    2. Kim WY,
    3. Ahmed M,
    4. Choi S,
    5. Kim J,
    6. Han DW
    (2015) The use of complementary and alternative medicine by Korean breast cancer women:is It associated with severity of symptoms?Hindawi, 2015:1–7.
  30. ↵
    1. Jones D,
    2. Cohen L,
    3. Rieber AG,
    4. Urbauer D,
    5. Fellman B,
    6. Fisch MJ,
    7. Nazario A
    (2018) Complementary and alternative medicine use in minority and medically underserved oncology patients:assessment and implications. Integr Cancer Ther 17:371–379.
    OpenUrl
  31. ↵
    1. Bairati I,
    2. Meyer F,
    3. Gélinas M,
    4. Fortin A,
    5. Nabid A,
    6. Brochet F,
    7. et al.
    (2005) Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 23:5805–5813.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Alwhaibi M,
    2. Sambamoorthi U
    (2016) Sex differences in the use of complementary and alternative medicine among adults with multiple chronic conditions. Evid Based Complement Alternat Med 2016:2067095.
    OpenUrl
  33. ↵
    1. Mohammad Y,
    2. Al-Ahmari A,
    3. Al-Dashash F,
    4. Al-Hussain F,
    5. Al-Masnour F,
    6. Masoud A,
    7. et al.
    (2015) Pattern of traditional medicine use by adult Saudi patients with neurological disorders. BMC Complement Altern Med 15:102.
    OpenUrl
  34. ↵
    1. Wada A,
    2. Sakaeda T,
    3. Takara K,
    4. Hirai M,
    5. Kimura T,
    6. Ohmoto N,
    7. et al.
    (2002) Effects of St John's wort and hypericin on cytotoxicity of anticancer drugs. Drug Metab Pharmacokinet 17:467–474.
    OpenUrlCrossRefPubMed
  35. ↵
    1. John GM,
    2. Hershman DL,
    3. Falci L,
    4. Shi Z,
    5. Tsai WY,
    6. Greenlee H
    (2016) Complementary and alternative medicine use among US cancer survivors. J Cancer Surviv 10:850–864.
    OpenUrl
  36. ↵
    1. Foster BC,
    2. Foster MS,
    3. Vandenhoek S,
    4. Krantis A,
    5. Budzinski JW,
    6. Arnason JT,
    7. et al.
    (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4:176–184.
    OpenUrlPubMedWeb of Science
  37. ↵
    1. Chen HW,
    2. Tsai CW,
    3. Yang JJ,
    4. Liu CT,
    5. Kuo WW,
    6. Lii CK
    (2003) The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats. Br J Nutr 89:189–200.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Sparreboom A,
    2. Cox MC,
    3. Acharya MR,
    4. Figg WD
    (2004) Herbal remedies in the United States:potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Sikkema RS,
    2. Farag E,
    3. Himatt S,
    4. Ibrahim AK,
    5. Al-Romaihi H,
    6. Al-Marri SA,
    7. et al.
    (2017) Risk Factors for primary middle east respiratory syndrome coronavirus infection in camel workers in Qatar during 2013-2014:A case-control study. J Infect Dis 215:1702–1705.
    OpenUrl
    1. Reusken CB,
    2. Farag EA,
    3. Jonges M,
    4. Godeke GJ,
    5. El-Sayed AM,
    6. Pas SD,
    7. et al.
    (2014) Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014. Euro Surveill 19:20829.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Omer MM,
    2. Musa MT,
    3. Bakhiet MR,
    4. Perrett L
    (2010) Brucellosis in camels, cattle and humans:associations and evaluation of serological tests used for diagnosis of the disease in certain nomadic localities in Sudan. Rev Sci Tech 29:663–669.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords